# Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Canonical URL: https://biopharmsignal.com/news/REGN/dupixentr-dupilumab-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria-csu
Ticker: REGN
Company: Regeneron Pharmaceuticals
Source: Regeneron Pharmaceuticals
Published: 2026-04-13 05:00 EST
Original Source URL: https://investor.regeneron.com
## Summary

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults The latest approval expands Dupixent’s

## Article Body
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults The latest approval expands Dupixent’s
## Recent Company News
- 2026-06-04 11:00 EST — [Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO](https://biopharmsignal.com/news/REGN/regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-disease-pipelines-at-ada-and-endo) — Source: Regeneron Pharmaceuticals
- 2026-05-28 20:00 EST — [Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak](https://biopharmsignal.com/news/REGN/regeneron-s-ebola-antibody-recommended-by-world-health-organization-for-investigational-use-in-response-to-current-bundibugyo-ebolavirus-outbreak) — Source: Regeneron Pharmaceuticals
- 2026-05-22 11:00 EST — [Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss](https://biopharmsignal.com/news/REGN/otarmenitm-lunsotogene-parvec-receives-ema-filing-acceptance-for-genetic-hearing-loss) — Source: Regeneron Pharmaceuticals
- 2026-05-21 21:01 EST — [Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis](https://biopharmsignal.com/news/REGN/lynozyficr-linvoseltamab-monotherapy-demonstrates-deep-and-rapid-responses-in-all-treated-patients-with-second-line-plus-systemic-amyloid-light-chain-amyloidosis) — Source: Regeneron Pharmaceuticals
- 2026-05-18 11:00 EST — [Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas](https://biopharmsignal.com/news/REGN/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicontm-conjugates-across-multiple-therapeutic-areas) — Source: Regeneron Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)